Exelixis Inc
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyro… Read more
Exelixis Inc (EXEL) - Net Assets
Latest net assets as of December 2025: $2.16 Billion USD
Based on the latest financial reports, Exelixis Inc (EXEL) has net assets worth $2.16 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.84 Billion) and total liabilities ($683.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.16 Billion |
| % of Total Assets | 75.98% |
| Annual Growth Rate | N/A |
| 5-Year Change | -2.23% |
| 10-Year Change | 2319.8% |
| Growth Volatility | 130.04 |
Exelixis Inc - Net Assets Trend (1999–2025)
This chart illustrates how Exelixis Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Exelixis Inc (1999–2025)
The table below shows the annual net assets of Exelixis Inc from 1999 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $2.16 Billion | -3.69% |
| 2024-12-31 | $2.24 Billion | -0.87% |
| 2023-12-31 | $2.26 Billion | -9.02% |
| 2022-12-31 | $2.49 Billion | +12.57% |
| 2021-12-31 | $2.21 Billion | +17.64% |
| 2020-12-31 | $1.88 Billion | +11.46% |
| 2019-12-31 | $1.69 Billion | +30.95% |
| 2018-12-31 | $1.29 Billion | +351.80% |
| 2017-12-31 | $284.96 Million | +219.04% |
| 2016-12-31 | $89.32 Million | +185.63% |
| 2015-12-31 | $-104.30 Million | +9.17% |
| 2014-12-31 | $-114.83 Million | -273.36% |
| 2013-12-31 | $66.24 Million | -77.66% |
| 2012-12-31 | $296.43 Million | +227.07% |
| 2011-12-31 | $90.63 Million | +139.69% |
| 2010-12-31 | $-228.32 Million | -39.46% |
| 2009-12-31 | $-163.72 Million | -191.01% |
| 2008-12-31 | $-56.26 Million | -165.79% |
| 2007-12-31 | $85.51 Million | -5.63% |
| 2006-12-31 | $90.61 Million | +58.15% |
| 2005-12-31 | $57.30 Million | +13.07% |
| 2004-12-31 | $50.67 Million | -68.62% |
| 2003-12-31 | $161.48 Million | -8.21% |
| 2002-12-31 | $175.92 Million | -25.84% |
| 2001-12-31 | $237.22 Million | +44.84% |
| 2000-12-31 | $163.78 Million | +5949.21% |
| 1999-12-31 | $-2.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Exelixis Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4082400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $262.00K | 0.01% |
| Other Comprehensive Income | $3.48 Million | 0.16% |
| Other Components | $2.23 Billion | 103.38% |
| Total Equity | $2.16 Billion | 100.00% |
Exelixis Inc Competitors by Market Cap
The table below lists competitors of Exelixis Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Orion Oyj A
HE:ORNAV
|
$8.67 Billion |
|
CapitaLand Integrated Commercial Trust
PINK:CPAMF
|
$8.67 Billion |
|
Wintrust Financial Corporation
NASDAQ:WTFC
|
$8.68 Billion |
|
CATHAY PAC.AIRW.HD-20ADR5
F:CTYA
|
$8.70 Billion |
|
SharkNinja, Inc.
NYSE:SN
|
$8.64 Billion |
|
Brixmor Property
NYSE:BRX
|
$8.61 Billion |
|
Centrica plc
PINK:CPYYF
|
$8.61 Billion |
|
Celsius Holdings Inc
NASDAQ:CELH
|
$8.60 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Exelixis Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,244,203,000 to 2,161,319,000, a change of -82,884,000 (-3.7%).
- Net income of 782,570,000 contributed positively to equity growth.
- Share repurchases of 947,511,000 reduced equity.
- Other comprehensive income increased equity by 4,823,000.
- Other factors increased equity by 77,234,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $782.57 Million | +36.21% |
| Share Repurchases | $947.51 Million | -43.84% |
| Other Comprehensive Income | $4.82 Million | +0.22% |
| Other Changes | $77.23 Million | +3.57% |
| Total Change | $- | -3.69% |
Book Value vs Market Value Analysis
This analysis compares Exelixis Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.36x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $-5.94 | $41.07 | x |
| 1999-12-31 | $-0.47 | $41.07 | x |
| 2000-12-31 | $5.24 | $41.07 | x |
| 2001-12-31 | $5.10 | $41.07 | x |
| 2002-12-31 | $3.11 | $41.07 | x |
| 2003-12-31 | $2.47 | $41.07 | x |
| 2004-12-31 | $0.70 | $41.07 | x |
| 2005-12-31 | $0.43 | $41.07 | x |
| 2006-12-31 | $0.61 | $41.07 | x |
| 2007-12-31 | $0.73 | $41.07 | x |
| 2008-12-31 | $-0.54 | $41.07 | x |
| 2009-12-31 | $-1.53 | $41.07 | x |
| 2010-12-31 | $-2.10 | $41.07 | x |
| 2011-12-31 | $0.69 | $41.07 | x |
| 2012-12-31 | $1.85 | $41.07 | x |
| 2013-12-31 | $0.36 | $41.07 | x |
| 2014-12-31 | $-0.59 | $41.07 | x |
| 2015-12-31 | $-0.50 | $41.07 | x |
| 2016-12-31 | $0.36 | $41.07 | x |
| 2017-12-31 | $0.91 | $41.07 | x |
| 2018-12-31 | $4.12 | $41.07 | x |
| 2019-12-31 | $5.35 | $41.07 | x |
| 2020-12-31 | $5.91 | $41.07 | x |
| 2021-12-31 | $6.86 | $41.07 | x |
| 2022-12-31 | $7.67 | $41.07 | x |
| 2023-12-31 | $7.04 | $41.07 | x |
| 2024-12-31 | $7.58 | $41.07 | x |
| 2025-12-31 | $7.67 | $41.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Exelixis Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 36.21%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 33.73%
- • Asset Turnover: 0.82x
- • Equity Multiplier: 1.32x
- Recent ROE (36.21%) is above the historical average (-43.38%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | 0.00% | -689.52% | 0.25x | 0.00x | $-12.16 Million |
| 1999 | 0.00% | -178.10% | 0.56x | 0.00x | $-18.42 Million |
| 2000 | -46.28% | -304.18% | 0.12x | 1.26x | $-91.58 Million |
| 2001 | -30.01% | -173.60% | 0.12x | 1.46x | $-94.91 Million |
| 2002 | -48.96% | -194.33% | 0.13x | 1.93x | $-103.72 Million |
| 2003 | -58.69% | -183.88% | 0.14x | 2.22x | $-110.92 Million |
| 2004 | -270.86% | -259.65% | 0.18x | 5.75x | $-142.31 Million |
| 2005 | -251.63% | -111.11% | 0.23x | 9.92x | $-87.76 Million |
| 2006 | -193.17% | -102.86% | 0.25x | 7.53x | $-106.75 Million |
| 2007 | -119.84% | -76.13% | 0.28x | 5.72x | $-93.59 Million |
| 2008 | 0.00% | -138.18% | 0.29x | 0.00x | $-157.16 Million |
| 2009 | 0.00% | -89.10% | 0.44x | 0.00x | $-118.85 Million |
| 2010 | 0.00% | -49.90% | 0.51x | 0.00x | $-69.50 Million |
| 2011 | 83.52% | 26.14% | 0.74x | 4.34x | $66.63 Million |
| 2012 | -49.81% | -311.16% | 0.07x | 2.43x | $-177.29 Million |
| 2013 | -369.52% | -781.03% | 0.06x | 7.60x | $-251.38 Million |
| 2014 | 0.00% | -1069.42% | 0.08x | 0.00x | $-257.06 Million |
| 2015 | 0.00% | -456.63% | 0.11x | 0.00x | $-159.31 Million |
| 2016 | -78.62% | -36.68% | 0.32x | 6.69x | $-79.15 Million |
| 2017 | 54.12% | 34.09% | 0.69x | 2.30x | $125.73 Million |
| 2018 | 53.60% | 80.82% | 0.60x | 1.10x | $561.32 Million |
| 2019 | 19.04% | 33.17% | 0.51x | 1.12x | $152.41 Million |
| 2020 | 5.95% | 11.32% | 0.46x | 1.14x | $-76.13 Million |
| 2021 | 10.45% | 16.10% | 0.55x | 1.18x | $10.00 Million |
| 2022 | 7.33% | 11.31% | 0.52x | 1.23x | $-66.56 Million |
| 2023 | 9.18% | 11.35% | 0.62x | 1.30x | $-18.63 Million |
| 2024 | 23.23% | 24.04% | 0.74x | 1.31x | $296.85 Million |
| 2025 | 36.21% | 33.73% | 0.82x | 1.32x | $566.44 Million |
Industry Comparison
This section compares Exelixis Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Exelixis Inc (EXEL) | $2.16 Billion | 0.00% | 0.32x | $8.66 Billion |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |